These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32978807)

  • 21. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.
    Forcina A; Lorentino F; Marasco V; Oltolini C; Marcatti M; Greco R; Lupo-Stanghellini MT; Carrabba M; Bernardi M; Peccatori J; Corti C; Ciceri F
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1476-1482. PubMed ID: 29501780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
    Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
    Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
    Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
    Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Zhang Y; Chen H; Song Y; Tan X; Zhao Y; Liu X; Li Z; Yang F; Jiang M; Gao Z; Wu T
    Br J Haematol; 2020 Apr; 189(1):146-152. PubMed ID: 31869864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
    López-Corral L; Caballero-Velázquez T; López-Godino O; Rosiñol L; Pérez-Vicente S; Fernandez-Avilés F; Krsnik I; Morillo D; Heras I; Morgades M; Rifon JJ; Sampol A; Iniesta F; Ocio EM; Martin J; Rovira M; Cabero M; Castilla-Llorente C; Ribera JM; Torres-Juan M; Moraleda JM; Martinez C; Vázquez A; Gutierrez G; Caballero D; San Miguel JF; Mateos MV; Pérez-Simón JA
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1703-1712. PubMed ID: 31054983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
    Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.
    Leon Rodriguez E; Rivera Franco MM; Perez Alvarez SI
    Ann Hematol; 2017 Sep; 96(9):1525-1531. PubMed ID: 28691152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
    Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
    Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
    Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
    Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia.
    Salas MQ; Prem S; Atenafu EG; Law AD; Lam W; Al-Shaibani Z; Loach D; Kim DDH; Michelis FV; Lipton JH; Kumar R; Mattsson J; Viswabandya A
    Eur J Haematol; 2019 Nov; 103(5):510-518. PubMed ID: 31449699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Fujita N; Kobayashi R; Atsuta Y; Iwasaki F; Suzumiya J; Sasahara Y; Inoue M; Koh K; Hori T; Goto H; Ichinohe T; Hashii Y; Kato K; Suzuki R; Mitsui T
    Int J Hematol; 2019 Apr; 109(4):483-490. PubMed ID: 30701466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
    Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.